JPMorgan Chase & Co. Has $39.09 Million Stock Holdings in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

JPMorgan Chase & Co. decreased its stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 0.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 903,415 shares of the company’s stock after selling 6,661 shares during the period. JPMorgan Chase & Co. owned approximately 3.23% of Establishment Labs worth $39,091,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Rice Hall James & Associates LLC raised its position in shares of Establishment Labs by 10.7% during the third quarter. Rice Hall James & Associates LLC now owns 793,300 shares of the company’s stock valued at $34,326,000 after buying an additional 76,959 shares during the last quarter. Bamco Inc. NY increased its holdings in Establishment Labs by 13.6% in the 3rd quarter. Bamco Inc. NY now owns 489,386 shares of the company’s stock valued at $21,176,000 after buying an additional 58,611 shares during the period. William Blair Investment Management LLC raised its stake in shares of Establishment Labs by 14.5% in the 2nd quarter. William Blair Investment Management LLC now owns 481,572 shares of the company’s stock valued at $21,883,000 after buying an additional 60,848 shares in the last quarter. Sofinnova Investments Inc. raised its stake in shares of Establishment Labs by 204.1% in the 2nd quarter. Sofinnova Investments Inc. now owns 429,244 shares of the company’s stock valued at $19,505,000 after buying an additional 288,082 shares in the last quarter. Finally, First Turn Management LLC bought a new position in shares of Establishment Labs during the 2nd quarter worth about $16,812,000. Institutional investors own 72.91% of the company’s stock.

Wall Street Analysts Forecast Growth

ESTA has been the topic of a number of analyst reports. Citigroup upped their target price on shares of Establishment Labs from $45.00 to $50.00 and gave the company a “neutral” rating in a research note on Tuesday, October 1st. BTIG Research boosted their price target on Establishment Labs from $62.00 to $65.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Finally, Stephens upgraded Establishment Labs to a “strong-buy” rating in a research report on Monday, December 2nd. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Establishment Labs currently has a consensus rating of “Buy” and a consensus target price of $60.60.

Establishment Labs Trading Up 2.2 %

ESTA stock opened at $46.26 on Monday. The business has a fifty day moving average price of $44.09 and a 200 day moving average price of $43.63. The company has a debt-to-equity ratio of 5.94, a current ratio of 3.62 and a quick ratio of 2.29. Establishment Labs Holdings Inc. has a fifty-two week low of $24.43 and a fifty-two week high of $60.12. The stock has a market capitalization of $1.30 billion, a price-to-earnings ratio of -17.93 and a beta of 1.16.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.